NEW YORK, May 31, 2013 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced that trading of Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company, commenced on The NASDAQ Stock Market on Friday, May 31, 2013. Kamada Ltd. is now dually-listed on The NASDAQ Stock Market and the Tel Aviv Stock Exchange under the ticker symbol KMDA.
Kamada an orphan drug focused, plasma-derived protein therapeutics company with an existing marketed product portfolio and a robust late-stage product pipeline. Kamada develops and produces specialty plasma-derived protein therapeutics and currently market these products through strategic partners in the United States and directly, through local distributors, in several emerging markets. The Company's uses its proprietary platform technology for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (''AAT'') in a high purity, liquid form, as well as other plasma-derived proteins. Kamada's flagship product, Glassia, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration is marketed through a strategic partnership with Baxter International Inc. in the U.S. The Company also has a product line of nine other injectable pharmaceutical products, which are marketed in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada currently has five plasma-derived protein products in its development pipeline, including an inhaled formulation of AAT for treatment of AAT deficiency that is in pivotal Phase II/III clinical trials in Europe and is entering into Phase II clinical trials in the U.S. In addition, Kamada leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing ten complementary products in Israel that are manufactured by third parties.
"NASDAQ congratulates Kamada on its listing on The NASDAQ Stock Market, which will continue to provide the company with the opportunity to strengthen its global presence while continuing to market its existing successful therapeutics in the U.S. market," said Nelson Griggs, Senior Vice President, NASDAQ OMX. "We are happy to be the exchange of choice for Kamada's U.S. listing and look forward to celebrating many milestones with Kamada and its shareholders in the years to come."
Since its inception, NASDAQ OMX has consistently been the exchange of choice for progressive and cutting-edge healthcare companies Kamada Ltd., Portola Pharmaceuticals, Chimerix Inc. and Tetraphase Pharmaceuticals Inc which are among the healthcare companies to list on The NASDAQ Stock Market in 2013. The NASDAQ Stock Market is currently home to more than 70% of healthcare companies listed on U.S. markets.
About NASDAQ OMX
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (http://www.facebook.com/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
CONTACT: Jennifer Knapp +1 212 401 8916 Jennifer.Knapp@nasdaqomx.com
Source:The NASDAQ OMX Group, Inc.